Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. Show more
Location: | Website: www.sppirx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$1.03
Open
$1.03
Volume
N/A
Day Range
$1.03 - $1.03
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
9.68%
Institutional Own.
22.70%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ROLVEDON™ (ex ROLONTIS™) (eflapegrastim) Details Blood disorder, Genetic disorder, Achromatopsia | Approved Update | |
Poziotinib Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |